Asian Spectator


The Times

.

Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China

  • Written by ACN Newswire - Press Releases

Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China

TOKYO, Apr 1, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Seikagaku announced today that the companies have entered into an agreement for the co-development and marketing alliance in China for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku.

On the basis of this agreement, the...

Magazine

Compressed Air Pipe and Fittings: What Every Australian Industrial Facility Needs to Know

Compressed air is the fourth utility of modern industry, right alongside electricity, gas, and water. Yet despite its critical role in powering everything from pneumatic tools to automated productio...

Common Risks Hidden in Commercial Lease Agreements

Commercial leases are often longer and more complex than tenants expect, and the fine print can carry significant financial and operational consequences over the years that follow. Many business own...

Corporate Secretarial Services in Singapore: Annual Compliance, Key Filings, and Common Mistake

Annual compliance in Singapore should not be treated as a once-a-year administrative event. It is an ongoing governance system that depends on accurate records, timely filings, disciplined approvals...

hacklink hack forum hacklink film izle hacklink z-librarytelegram下载betwoonzlibrary.jojobetสล็อตสล็อตgrandpashabetstakecasibomStreamEastStreamEasthitbet girişroyalbetjojobetjojobetdamabetPadişahbetvipparkmobiladres.comDizipalStreamEastPadişahbetGalabetmostbetmarsbahismarsbahiskralbetkralbetmeritkingSuperbetinjojobetcasibomjojobetjojobet